Introduction: Who Should Undergo Diagnostics

Gastrointestinal carcinoma, also known as gastrointestinal cancer, refers to cancers that develop anywhere along the digestive tract, which includes the esophagus, stomach, small intestine, colon, rectum, pancreas, liver, and other digestive organs. Because symptoms often don’t appear until the cancer has advanced, understanding when to seek diagnostic testing is crucial for early detection and better outcomes.^[1]

Most people should consider diagnostic testing if they experience persistent or unusual symptoms related to their digestive system. These warning signs may include ongoing stomach pain or discomfort, unexplained weight loss, changes in bowel habits that last more than a few weeks, difficulty swallowing, persistent heartburn or indigestion, bloody or very dark stools, nausea and vomiting that won’t go away, or a feeling of being bloated or full even after eating small amounts.^[1][6]

It’s important to understand that many of these symptoms can also be caused by conditions that are not cancer. However, because gastrointestinal cancers often remain silent in their early stages, seeking medical attention when symptoms persist is essential. Early detection dramatically improves survival rates, making timely diagnostics a critical component of cancer care.^[4]

People at higher risk should be especially vigilant about seeking diagnostics. Risk factors include being over 65 years old, being male, having a family history of gastrointestinal cancer, having certain infections like Helicobacter pylori (a type of bacteria that can infect the stomach), having conditions like gastroesophageal reflux disease (GERD) or chronic gastritis, smoking, heavy alcohol use, obesity, and a diet high in salty, smoked, or processed foods.^[1][2]

For colorectal cancer specifically, screening should now begin at age 45 for most people, even without symptoms. This change reflects the concerning trend of increasing colorectal cancer cases in younger adults. Those with a family history of gastrointestinal cancers or certain genetic conditions may need to start screening even earlier.^[1]

Classic Diagnostic Methods

When doctors suspect gastrointestinal cancer, they use a combination of tests to confirm the diagnosis, determine the exact location and type of cancer, and assess how far it may have spread. This comprehensive approach helps distinguish gastrointestinal cancer from other conditions that may cause similar symptoms.^[1]

Endoscopic Procedures

Endoscopy is one of the most important tools for diagnosing gastrointestinal cancers. During this procedure, a doctor inserts a thin, flexible tube called an endoscope through the mouth or rectum. This tube has a tiny camera and light at the end, allowing the doctor to see the lining of the digestive organs directly on a screen. Different types of endoscopy examine different parts of the digestive system.^[1]

An esophagogastroduodenoscopy, often shortened to EGD or upper endoscopy, allows doctors to examine the esophagus, stomach, and the beginning of the small intestine. The patient is usually sedated to make the procedure more comfortable. If the doctor sees anything suspicious, they can take small tissue samples called biopsies during the same procedure. These tissue samples are then examined under a microscope to look for cancer cells.^[1][11]

Colonoscopy examines the colon and rectum by inserting the endoscope through the anus. This procedure not only helps detect cancer but can also find and remove polyps, which are small growths that can become cancerous over time. Removing polyps during colonoscopy can actually prevent colorectal cancer from developing, making this both a diagnostic and preventive procedure.^[1]

Sigmoidoscopy is similar to colonoscopy but examines only the lower part of the colon and rectum. It may be used when only this area needs evaluation. For more detailed examination, doctors may also perform endoscopic ultrasound, which combines endoscopy with ultrasound imaging to see how deeply a tumor has grown into the wall of the digestive organ and whether nearby lymph nodes are affected.^[1]

Imaging Studies

Imaging tests create pictures of the inside of the body and help doctors see tumors, determine their size, and check whether cancer has spread to other organs. Several types of imaging are commonly used in diagnosing gastrointestinal cancers.^[1]

A computed tomography scan, or CT scan, uses X-rays taken from different angles and combines them with computer processing to create detailed cross-sectional images of the body. CT scans are particularly useful for seeing the pancreas, liver, and other abdominal organs, and they can show whether cancer has spread beyond its original location.^[1]

Magnetic resonance imaging, or MRI, uses powerful magnets and radio waves instead of X-rays to create detailed images of soft tissues. MRI scans are especially helpful for examining the liver and other organs in great detail. They can sometimes detect smaller tumors that might not show up clearly on CT scans.^[1]

Ultrasound uses sound waves to create images of internal organs. It’s completely painless and doesn’t use radiation. Doctors may use regular ultrasound on the outside of the body or endoscopic ultrasound, where the ultrasound probe is attached to an endoscope and inserted into the digestive tract for more detailed images.^[1]

Positron emission tomography, or PET scan, involves injecting a small amount of radioactive sugar into the bloodstream. Cancer cells, which use more energy than normal cells, absorb more of this sugar and show up as bright spots on the scan. PET scans are often combined with CT scans to provide both anatomical and functional information about potential cancer.^[1]

Traditional X-rays may also be used, sometimes with a substance called barium that the patient swallows or receives as an enema. Barium shows up clearly on X-rays and outlines the digestive tract, making it easier to see abnormalities. A barium swallow examines the esophagus and stomach, while a barium enema examines the colon and rectum.^[1]

Laboratory Tests

Blood tests play an important supporting role in diagnosing gastrointestinal cancers, though they usually cannot confirm cancer on their own. These tests look for changes in the blood that could be signs of cancer or other problems.^[1]

Doctors may check for anemia, which is a low red blood cell count that can result from bleeding tumors in the digestive tract. They may also look for signs of liver or kidney problems, which could indicate that cancer has spread to these organs or that the cancer is affecting how these organs work.^[1]

A fecal occult blood test checks stool samples for tiny amounts of blood that aren’t visible to the naked eye. While blood in the stool can have many causes besides cancer, a positive test may prompt further investigation with colonoscopy or other tests.^[1]

Biopsy and Tissue Analysis

A biopsy is the removal of a small piece of tissue for examination under a microscope. It is the only way to definitively confirm that a tumor is cancerous and determine what type of cancer cells are present. Most biopsies for gastrointestinal cancers are performed during endoscopic procedures, where the doctor can see suspicious areas and remove tissue samples without additional surgery.^[1]

Once a biopsy is taken, a specialist called a pathologist examines the tissue under a microscope. The pathologist looks at the structure and appearance of the cells to determine whether they are cancerous, what type of cancer it is, and how abnormal the cells look. More abnormal-looking cells tend to grow faster and may require more aggressive treatment.^[4]

Diagnostics for Clinical Trial Qualification

Clinical trials are research studies that test new treatments or combinations of treatments for cancer. To ensure patient safety and produce reliable results, clinical trials have specific requirements about who can participate. These requirements are called eligibility criteria, and meeting them depends on certain diagnostic tests.^[12]

One of the most important requirements for entering a clinical trial is having a confirmed diagnosis through biopsy. Researchers need to know exactly what type of cancer a patient has and verify it through examination of tissue under a microscope. This ensures that everyone in the trial has the same type of cancer and that results can be compared accurately.^[14]

Staging tests are also essential for clinical trial qualification. Staging describes how large the tumor is, whether it has spread to lymph nodes, and whether it has spread to distant organs. Most clinical trials specify which stage of cancer they’re studying. Staging typically requires a combination of imaging tests like CT scans, MRI scans, or PET scans to get a complete picture of where the cancer is located in the body.^[12]

Blood tests are used to assess a patient’s overall health and organ function before entering a clinical trial. Trials often have requirements about kidney function, liver function, and blood cell counts. These tests help ensure that patients are healthy enough to tolerate the experimental treatment and that researchers can safely monitor them during the study.^[12]

Biomarker testing has become increasingly important for clinical trial qualification, especially as treatments become more personalized. Biomarkers are substances in the body, or characteristics of cancer cells, that can predict how a cancer will behave or how it might respond to certain treatments. Several biomarkers are particularly important in gastrointestinal cancers.^[14]

HER2 testing looks for a protein called human epidermal growth factor receptor 2 on cancer cells. Some stomach cancers have high levels of HER2, and these cancers may respond to drugs that specifically target this protein. Clinical trials testing these targeted drugs require patients to have HER2-positive tumors.^[15]

Microsatellite instability, or MSI, testing examines the cancer’s DNA for certain types of genetic errors. Cancers with high microsatellite instability (called MSI-high) often respond very well to immunotherapy drugs, which help the immune system attack cancer cells. Many clinical trials studying immunotherapy for gastrointestinal cancers require or prefer patients with MSI-high tumors.^[14][15]

PD-L1 testing measures the amount of a protein called programmed death ligand 1 on cancer cells. Higher levels of PD-L1 may indicate that a tumor is more likely to respond to certain immunotherapy drugs. Some clinical trials require specific PD-L1 levels for patient enrollment.^[14][15]

Testing for tumor mutation burden, or TMB, counts the number of mutations present in cancer cells. Cancers with many mutations may be more visible to the immune system and more likely to respond to immunotherapy. This test is becoming more common in clinical trial eligibility requirements.^[14]

Some trials test for Epstein-Barr virus (EBV) in stomach cancer tissue. EBV-positive stomach cancers have different characteristics and may respond differently to certain treatments, so some studies specifically target this subgroup of patients.^[14]

Beyond these molecular tests, clinical trials may require additional diagnostic procedures to establish baseline information. This might include specialized imaging to measure tumor size accurately, so researchers can track whether the treatment is shrinking the tumor. Some trials require endoscopic ultrasound for precise staging or additional biopsies to collect more tissue for research purposes.^[12]

Performance status assessments evaluate how well a patient can perform daily activities and whether the cancer is affecting their ability to care for themselves. While not a traditional diagnostic test, this assessment is a standard requirement for clinical trial entry and helps researchers understand whether a patient is strong enough for the experimental treatment.^[12]

Some clinical trials studying specific aspects of gastrointestinal cancer may have unique diagnostic requirements. For example, trials examining how diet or lifestyle affects cancer might require detailed nutritional assessments or measurements of how the body processes food after stomach surgery. Trials testing drugs to prevent cancer from spreading might require very detailed imaging to ensure no spread has occurred at the time of enrollment.^[14]